If ISR-inhibition is a physiologic counterpart of leukemia suppression, sustained ISR activation, due to decreased Triad1 during leukemogenesis, may contribute to disease progression in this molecular subset of adverse prognosis AML. The gene discussed is ARIH2; the disease is acute myeloid leukemia.